Jazz Pharma Q2 Revenue Beats, Raises 2026 Guidance on Zepzelca Strength
JAZZ has more than doubled off its 52-week low of $105.
Summary
Jazz Pharmaceuticals delivered a strong Q2 with revenue of $1.21B, beating consensus by $90M, driven by 42% growth in Zepzelca sales. Adjusted EPS of $5.71 missed estimates by $0.47, but the top-line beat and raised full-year guidance to $4.60-$4.75B signal robust demand across key products. Xywav added 525 net patients, and Epidiolex grew 16%, reinforcing the growth narrative. This follows the Phase 3 setback for Zepzelca in June, but the commercial momentum in first-line ES-SCLC appears unaffected. The upcoming PDUFA date for Ziihera on August 25 could provide another catalyst if approved.
At the time of this announcement, JAZZ was trading at $261.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.8B. The 52-week trading range was $105.00 to $261.30. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.